¼¼°èÀÇ Áٱ⼼Æ÷ Ä¡·á ½ÃÀå : ½ÃÀå ºÐ¼® ¹× ¿¹Ãø(-2033³â) - À¯Çü, Á¦Ç°, ¼­ºñ½º, ±â¼ú, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ, ÇÁ·Î¼¼½º, Àåºñ, ¼Ö·ç¼Ç
Stem Cell Therapy Market Analysis and Forecast to 2033: Type, Product, Services, Technology, Application, End User, Process, Equipment, Solutions
»óǰÄÚµå : 1624257
¸®¼­Ä¡»ç : Global Insight Services LLC
¹ßÇàÀÏ : 2025³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 323 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,750 £Ü 6,872,000
Single User License help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇϸç, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 5,750 £Ü 8,319,000
Site License help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷(±¹°¡)ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,750 £Ü 9,766,000
Enterprise License help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ Àü ¼¼°è ¸ðµçºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°è Áٱ⼼Æ÷ Ä¡·áÁ¦ ½ÃÀåÀº 2023³â 119¾ï ´Þ·¯¿¡¼­ 2033³â 393¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµÇ¸ç, CAGRÀº ¾à 12.8%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù.

Áٱ⼼Æ÷ Ä¡·á ½ÃÀåÀº ¼Õ»óµÈ Á¶Á÷°ú Àå±â¸¦ º¹±¸, ´ëü, Àç»ýÇϱâ À§ÇØ Áٱ⼼Æ÷¸¦ ÀÌ¿ëÇÑ Ä¡·á¹ýÀ» °³¹ß ¹× Á¦°øÇÏ´Â »ê¾÷À» Æ÷°ýÇÕ´Ï´Ù. ÀÌ ½ÃÀå¿¡´Â Áٱ⼼Æ÷¸¦ ÀÌ¿ëÇÑ Á¦Ç°, ¿¬±¸ ¼­ºñ½º, ÀÓ»ó ÀÀ¿ë, ÷´Ü Ä¡·á ¼Ö·ç¼ÇÀÌ Æ÷ÇԵǸç, Àç»ýÀÇ·á, °³ÀÎ ¸ÂÃãÇü Ä¡·á, ¸¸¼ºÁúȯ °ü¸® µîÀÇ Çõ½ÅÀ» ÃËÁøÇÏ¿© ȯÀÚ Ä¡·á °á°ú¸¦ °³¼±ÇÒ ¼ö ÀÖ´Â Å« ÀáÀç·ÂÀ» °¡Áø ÇコÄɾ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù.

Àç»ýÀÇ·áÀÇ Çõ½Å°ú ÀÓ»ó Àû¿ë Áõ°¡¿¡ ÈûÀÔ¾î ½ÃÀåÀÌ ¹ßÀüÇϰí ÀÖ½À´Ï´Ù. ºÎ¹®º°·Î´Â µ¿Á¾ Áٱ⼼Æ÷ Ä¡·á°¡ ȯÀÚ Àû¿ë ¹üÀ§°¡ ³Ð°í Ä¡·á ±â°£ÀÌ Âª¾Æ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÀÚ°¡ Áٱ⼼Æ÷ Ä¡·á´Â °ÅºÎ¹ÝÀÀÀÇ À§ÇèÀ» ÃÖ¼ÒÈ­Çϸ鼭 ȯÀÚ °³°³Àο¡°Ô ¸ÂÃãÈ­µÈ Ä¡·á¹ýÀ» Á¦°øÇÕ´Ï´Ù. Áö¿ªº°·Î´Â ºÏ¹Ì°¡ ¿©ÀüÈ÷ Áö¹èÀûÀε¥, ÀÌ´Â ÇコÄɾî ÀÎÇÁ¶ó¿Í ´ë±Ô¸ð R&D ÅõÀÚ°¡ ±× ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. À¯·´Àº À¯¸®ÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©¿Í Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡¿¡ ÈûÀÔ¾î 2À§¸¦ Â÷ÁöÇß½À´Ï´Ù. ±¹°¡º°·Î´Â ¹Ì±¹ÀÌ ÃÖ÷´Ü »ý¸í°øÇÐ »ê¾÷°ú ¸·´ëÇÑ ÀڱݷÂÀ» ¹ÙÅÁÀ¸·Î ½ÃÀå ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. µ¶ÀÏÀº Àü·«Àû Á¦ÈÞ¿Í ÀÇ·á ±â¼ú Çõ½Å¿¡ ´ëÇÑ Á¤ºÎÀÇ Áö¿øÀ¸·Î °­·ÂÇÑ °æÀïÀÚ·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿ªÇÐ °ü°è´Â ±â¼ú ¹ßÀü°ú Àü·«Àû Á¦ÈÞ°¡ »õ·Î¿î Ä¡·áÀÇ °³Ã´À» À§ÇÑ ±æÀ» ¿­¾î Áö¼Ó °¡´ÉÇÑ ¼ºÀåÀÇ ¹ßÆÇÀ» ¸¶·ÃÇϰí ÀÖ´Â ±Þ¼ºÀåÇÏ´Â ½ÃÀå »óȲÀ» ¹Ý¿µÇÕ´Ï´Ù.

2023³â Áٱ⼼Æ÷ Ä¡·á ½ÃÀåÀº °ßÁ¶ÇÑ ¹°·® ¼ºÀåÀ» º¸À̸ç 2033³â¿¡´Â 120¸¸ °Ç¿¡¼­ 250¸¸ °ÇÀ¸·Î È®´ëµÉ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù. µ¿Á¾ Áٱ⼼Æ÷ Ä¡·á ºÐ¾ß´Â ±âÁõÀÚ ¸ÅĪ ±â¼úÀÇ ¹ßÀü°ú °ÅºÎ¹ÝÀÀ·ü °¨¼Ò·Î ÀÎÇØ 55%¶ó´Â Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ÀÚ°¡ Áٱ⼼Æ÷ Ä¡·á´Â 30%ÀÇ Á¡À¯À²À» Â÷ÁöÇÏ¸ç °³ÀÎ ¸ÂÃãÇü Ä¡·á Æ®·»µåÀÇ ¼öÇý¸¦ ¹Þ°í ÀÖ½À´Ï´Ù. ³ª¸ÓÁö 15%´Â Àΰø´Ù´É¼º Áٱ⼼Æ÷¸¦ Æ÷ÇÔÇÑ »õ·Î¿î Áٱ⼼Æ÷ ÀÀ¿ë ºÐ¾ß°¡ Â÷ÁöÇϰí Àִµ¥, ÀÌ´Â ´ÙÀç´Ù´ÉÇÔ°ú À±¸®Àû ÀÌÁ¡À¸·Î ÀÎÇØ Àα⸦ ²ø°í ÀÖ½À´Ï´Ù.

°æÀï ±¸µµ´Â Mesoblast Limited, Athersys, Inc, Novartis AG¿Í °°Àº ÁÖ¿ä ±â¾÷µéÀÌ Àü·«Àû ÆÄÆ®³Ê½Ê°ú Çõ½ÅÀ» ÅëÇØ ½ÃÀå ÁöÀ§¸¦ °­È­Çϰí ÀÖÀ¸¸ç, FDAÀÇ RMAT ÁöÁ¤ ¹× EMAÀÇ PRIME Á¦µµ¸¦ Æ÷ÇÔÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©´Â À¯¸ÁÇÑ Ä¡·áÁ¦ÀÇ ½ÂÀÎ °úÁ¤À» °¡¼ÓÈ­ÇÔÀ¸·Î½á ½ÃÀå ¿ªÇп¡ Å« ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ÇâÈÄ Àü¸ÁÀº R&D ÅõÀÚ Áõ°¡¿Í Àç»ýÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ÈûÀÔ¾î 2033³â±îÁö 15%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦ À庮°ú ³ôÀº ºñ¿ë µîÀÇ °úÁ¦´Â ¿©ÀüÈ÷ ³²¾Æ ÀÖÁö¸¸, ±â¼ú ¹ßÀüÀÌ »õ·Î¿î ±âȸ¸¦ âÃâÇÒ Å¼¼¸¦ °®Ãß°í ÀÖ¾î ½ÃÀå Àü¸ÁÀº ¿©ÀüÈ÷ ³«°üÀûÀÔ´Ï´Ù.

ÁÖ¿ä ±â¾÷

Mesoblast, Athersys, Pluristem Therapeutics, Fate Therapeutics, Gamida Cell, Brain Storm Cell Therapeutics, Vericel Corporation, Cytori Therapeutics, Cellular Biomedicine Group, Bio Cardia, Cynata Therapeutics, Re Neuron Group, Lineage Cell Therapeutics, Stemline Therapeutics, Orgenesis, Caladrius Biosciences, Kangstem Biotech, Stempeutics Research, Anterogen, Stem Cells

¸ñÂ÷

Á¦1Àå Áٱ⼼Æ÷ Ä¡·á ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå¿¡ °üÇÑ ÇÁ¸®¹Ì¾ö ÀλçÀÌÆ®

Á¦4Àå Áٱ⼼Æ÷ Ä¡·á ½ÃÀå Àü¸Á

Á¦5Àå Áٱ⼼Æ÷ Ä¡·á ½ÃÀå Àü·«

Á¦6Àå Áٱ⼼Æ÷ Ä¡·á ½ÃÀå ±Ô¸ð

Á¦7Àå Áٱ⼼Æ÷ Ä¡·á ½ÃÀå : À¯Çüº°

Á¦8Àå Áٱ⼼Æ÷ Ä¡·á ½ÃÀå : Á¦Ç°º°

Á¦9Àå Áٱ⼼Æ÷ Ä¡·á ½ÃÀå : ¼­ºñ½ºº°

Á¦10Àå Áٱ⼼Æ÷ Ä¡·á ½ÃÀå : ±â¼úº°

Á¦11Àå Áٱ⼼Æ÷ Ä¡·á ½ÃÀå : ¿ëµµº°

Á¦12Àå Áٱ⼼Æ÷ Ä¡·á ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

Á¦13Àå Áٱ⼼Æ÷ Ä¡·á ½ÃÀå : ÇÁ·Î¼¼½ºº°

Á¦14Àå Áٱ⼼Æ÷ Ä¡·á ½ÃÀå : ±â±âº°

Á¦15Àå Áٱ⼼Æ÷ Ä¡·á ½ÃÀå : ¼Ö·ç¼Çº°

Á¦16Àå Áٱ⼼Æ÷ Ä¡·á ½ÃÀå : Áö¿ªº°

Á¦17Àå °æÀï ±¸µµ

Á¦18Àå ±â¾÷ °³¿ä

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global stem cell therapy market is anticipated to expand from $11.9 billion in 2023 to $39.3 billion by 2033, with a CAGR of approximately 12.8%.

The stem cell therapy market encompasses the industry dedicated to developing and providing treatments that utilize stem cells to repair, replace, or regenerate damaged tissues and organs. This market includes stem cell-based products, research services, clinical applications, and advanced therapeutic solutions, driving innovations in regenerative medicine, personalized therapy, and chronic disease management, thereby revolutionizing healthcare with significant potential for enhanced patient outcomes.

The market is advancing, driven by innovations in regenerative medicine and increasing clinical applications. Among segments, the allogeneic stem cell therapy sub-segment leads, owing to its broader patient applicability and reduced time to treatment. Autologous therapies follow, offering personalized treatment options with minimized rejection risks. Geographically, North America remains the dominant region, fueled by healthcare infrastructure and significant R&D investments. Europe ranks as the second-highest performing region, supported by favorable regulatory frameworks and a growing emphasis on precision medicine. Within countries, the United States spearheads market growth, attributed to its cutting-edge biotech industry and substantial funding. Germany emerges as a strong contender, benefiting from strategic collaborations and government support for medical innovation. These dynamics reflect a burgeoning market landscape poised for sustained growth, with technological advancements and strategic partnerships paving the way for new therapeutic frontiers.

In 2023, the Stem Cell Therapy Market exhibited a robust volume trajectory, with the market projected to expand from 1.2 million treatments to 2.5 million treatments by 2033. The allogeneic stem cell therapy segment commands a substantial market share of 55%, driven by advancements in donor matching technologies and reduced rejection rates. Autologous therapies follow with a 30% share, benefiting from personalized treatment trends. The remaining 15% is occupied by emerging stem cell applications, including induced pluripotent stem cells, which are gaining traction due to their versatility and ethical advantages.

The competitive landscape is shaped by key players such as Mesoblast Limited, Athersys, Inc., and Novartis AG, each leveraging strategic partnerships and innovation to enhance their market positions. Regulatory frameworks, including the FDA's RMAT designation and EMA's PRIME scheme, significantly influence market dynamics by accelerating approval processes for promising therapies. Challenges, such as regulatory hurdles and high costs, persist, yet the market outlook remains optimistic, with technological advancements poised to unlock new opportunities.

Key Players

Mesoblast, Athersys, Pluristem Therapeutics, Fate Therapeutics, Gamida Cell, Brain Storm Cell Therapeutics, Vericel Corporation, Cytori Therapeutics, Cellular Biomedicine Group, Bio Cardia, Cynata Therapeutics, Re Neuron Group, Lineage Cell Therapeutics, Stemline Therapeutics, Orgenesis, Caladrius Biosciences, Kangstem Biotech, Stempeutics Research, Anterogen, Stem Cells

Sources

National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), International Society for Stem Cell Research (ISSCR), World Health Organization (WHO), National Stem Cell Foundation, California Institute for Regenerative Medicine (CIRM), Harvard Stem Cell Institute, Stanford University School of Medicine - Institute for Stem Cell Biology and Regenerative Medicine, Mayo Clinic Center for Regenerative Medicine, University of Cambridge - Stem Cell Institute, Max Planck Institute for Molecular Biomedicine, Kyoto University - Center for iPS Cell Research and Application, Karolinska Institute - Department of Cell and Molecular Biology, Australian Stem Cell Centre, International Society for Cellular Therapy (ISCT), Regenerative Medicine Foundation, World Stem Cell Summit, European Society of Gene and Cell Therapy (ESGCT), International Conference on Stem Cell Research and Therapy

Research Scope

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1: Stem Cell Therapy Market Overview

2: Executive Summary

3: Premium Insights on the Market

4: Stem Cell Therapy Market Outlook

5: Stem Cell Therapy Stem Cell Therapy Market Strategy

6: Stem Cell Therapy Market Size

7: Stem Cell Therapy Market, by Type

8: Stem Cell Therapy Market, by Product

9: Stem Cell Therapy Market, by Services

10: Stem Cell Therapy Market, by Technology

11: Stem Cell Therapy Market, by Application

12: Stem Cell Therapy Market, by End User

13: Stem Cell Therapy Market, by Process

14: Stem Cell Therapy Market, by Equipment

15: Stem Cell Therapy Market, by Solutions

16: Stem Cell Therapy Market, by Region

17: Competitive Landscape

18: Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â